Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • WHO agrees watered-down resolution on transparency in drug costs

    Countries at the World Health Organization agreed on Tuesday to push for clearer drug pricing, after watering down a draft resolution that would have also required pharmaceutical firms to disclose the cost of making medicines.

    02 June 2019 | Reuters
  • World Health Assembly Approves Milestone Resolution On Price Transparency

    The World Health Assembly today approved a milestone resolution to support greater public disclosure of prices for medicines and other health products – capping a nail-biting series of negotiations that continued until the very moment the measure came to the floor. In a highly unusual move, Germany, the United Kingdom and Hungary “disassociated” themselves from the measure, “Improving the transparency of markets for medicines, vaccines and other health products,” complaining that its far-reaching implications were not fully appreciated, and that the four-month review period since the draft resolution’s submission by lead sponsor Italy had been insufficient.

    02 June 2019 | Health Policy Watch
  • Is Off-Label HIV Prevention Better Than None?

    Rather than prescribe F/TDF as PrEP, Michael Saag, MD said, prescribers should sidestep the brand-name product and instead give their PrEP-eligible patients a generic HIV drug combination that uses lamivudine (3TC) with TDF.

    31 May 2019 | MedPage Today (requires free registration)
  • The truth is you can afford the medication that prevents HIV. Here’s how.

    It’s not the cost of PrEP that keeps more patients from accessing it; it’s the lack of awareness and the daunting nature of our complicated healthcare system.

    24 May 2019 | LGBTQ Nation
  • A Review of the Congressional Hearing on HIV Drug Pricing

    In an effort to best encapsulate the remarks of many of the members of the House and the powerful testimony of the HIV advocates present at the recent Congressional hearing on drug pricing around Gilead Sciences’ HIV prevention drug Truvada, we thought it was best to provide you with their own words.

    23 May 2019 | POZ
  • Analysis reveals extent of drug industry funding of UK patient organisations

    The researchers call for greater transparency to ensure that industry funding is not unduly influenced by commercial objectives.

    23 May 2019 | The BMJ press release
  • Medicare decides against tighter management of HIV drugs

    The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

    21 May 2019 | BioPharma Dive
  • Republicans defend drug company in spotlight over HIV medication prices

    Republican members of Congress defended Gilead, the leading manufacturer of HIV drugs in the U.S., during a testy hearing Thursday as Democrats blasted the company over the prices of its products.

    17 May 2019 | The Hill
  • Trump Administration Caves To Pharma On Medicare Part D 'Protected Classes' Reform

    The Trump administration has shelved a proposal that would have stymied egregious price hikes in the Medicare prescription drug program. It’s a major win for the drug industry, and a defeat for Trump’s goal of reducing drug prices.

    17 May 2019 | Forbes
  • A Leading HIV Drug Is Way Overpriced in the U.S.

    A House hearing over the price of Truvada shows a particularly glaring example of a rampant industry practice.

    17 May 2019 | Bloomberg
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.